163 related articles for article (PubMed ID: 37178702)
1. Molecular testing-guided therapy versus susceptibility testing-guided therapy in first-line and third-line Helicobacter pylori eradication: two multicentre, open-label, randomised controlled, non-inferiority trials.
Chen MJ; Chen PY; Fang YJ; Bair MJ; Chen CC; Chen CC; Yang TH; Lee JY; Yu CC; Kuo CC; Chiu MC; Chou CK; Chen CY; Hu WH; Tsai MH; Hsu YC; Shun CT; Luo JC; Lin JT; El-Omar EM; Wu MS; Liou JM;
Lancet Gastroenterol Hepatol; 2023 Jul; 8(7):623-634. PubMed ID: 37178702
[TBL] [Abstract][Full Text] [Related]
2. Second-line levofloxacin-based quadruple therapy versus bismuth-based quadruple therapy for Helicobacter pylori eradication and long-term changes to the gut microbiota and antibiotic resistome: a multicentre, open-label, randomised controlled trial.
Liou JM; Jiang XT; Chen CC; Luo JC; Bair MJ; Chen PY; Chou CK; Fang YJ; Chen MJ; Chen CC; Lee JY; Yang TH; Yu CC; Kuo CC; Chiu MC; Chen CY; Shun CT; Hu WH; Tsai MH; Hsu YC; Tseng CH; Chang CY; Lin JT; El-Omar EM; Wu MS;
Lancet Gastroenterol Hepatol; 2023 Mar; 8(3):228-241. PubMed ID: 36549320
[TBL] [Abstract][Full Text] [Related]
3. Susceptibility-guided sequential strategy versus empirical therapy for Helicobacter pylori infection: study protocol for a randomised controlled trial.
Lu K; Lang C; Zou X; Zang L; Sang W; Feng Q; Mu Y; Liu L; Xu C; Zhao J
Trials; 2023 Jun; 24(1):413. PubMed ID: 37337241
[TBL] [Abstract][Full Text] [Related]
4. Concomitant, bismuth quadruple, and 14-day triple therapy in the first-line treatment of Helicobacter pylori: a multicentre, open-label, randomised trial.
Liou JM; Fang YJ; Chen CC; Bair MJ; Chang CY; Lee YC; Chen MJ; Chen CC; Tseng CH; Hsu YC; Lee JY; Yang TH; Luo JC; Chang CC; Chen CY; Chen PY; Shun CT; Hsu WF; Hu WH; Chen YN; Sheu BS; Lin JT; Wu JY; El-Omar EM; Wu MS;
Lancet; 2016 Nov; 388(10058):2355-2365. PubMed ID: 27769562
[TBL] [Abstract][Full Text] [Related]
5. Efficacies of Genotypic Resistance-Guided vs Empirical Therapy for Refractory Helicobacter pylori Infection.
Liou JM; Chen PY; Luo JC; Lee JY; Chen CC; Fang YJ; Yang TH; Chang CY; Bair MJ; Chen MJ; Hsu YC; Hsu WF; Chang CC; Lin JT; Shun CT; El-Omar EM; Wu MS;
Gastroenterology; 2018 Oct; 155(4):1109-1119. PubMed ID: 29964036
[TBL] [Abstract][Full Text] [Related]
6. Long-term changes of gut microbiota, antibiotic resistance, and metabolic parameters after Helicobacter pylori eradication: a multicentre, open-label, randomised trial.
Liou JM; Chen CC; Chang CM; Fang YJ; Bair MJ; Chen PY; Chang CY; Hsu YC; Chen MJ; Chen CC; Lee JY; Yang TH; Luo JC; Chen CY; Hsu WF; Chen YN; Wu JY; Lin JT; Lu TP; Chuang EY; El-Omar EM; Wu MS;
Lancet Infect Dis; 2019 Oct; 19(10):1109-1120. PubMed ID: 31559966
[TBL] [Abstract][Full Text] [Related]
7. Helicobacter pylori eradication with a capsule containing bismuth subcitrate potassium, metronidazole, and tetracycline given with omeprazole versus clarithromycin-based triple therapy: a randomised, open-label, non-inferiority, phase 3 trial.
Malfertheiner P; Bazzoli F; Delchier JC; Celiñski K; Giguère M; Rivière M; Mégraud F;
Lancet; 2011 Mar; 377(9769):905-13. PubMed ID: 21345487
[TBL] [Abstract][Full Text] [Related]
8. 14-day tailored PCR-guided triple therapy versus 14-day non-Bismuth concomitant quadruple therapy for Helicobacter pylori eradication: A multicenter, open-label randomized noninferiority controlled trial.
Amiot A; Hacoon J; Heluwaert F; Mion F; Lamarque D; Moussata D; Mimouni M; Delchier JC; Durand-Zaleski I; Audureau E; Bastuji-Garin S;
Helicobacter; 2024; 29(2):e13076. PubMed ID: 38680067
[TBL] [Abstract][Full Text] [Related]
9. Empiric Versus Clarithromycin Resistance-Guided Therapy for Helicobacter pylori Based on Polymerase Chain Reaction Results in Patients With Gastric Neoplasms or Gastric Mucosa-Associated Lymphoid Tissue Lymphoma: A Randomized Controlled Trial.
Kim JL; Cho SJ; Chung SJ; Lee A; Choi J; Chung H; Kim SG
Clin Transl Gastroenterol; 2020 Sep; 11(9):e00194. PubMed ID: 33094958
[TBL] [Abstract][Full Text] [Related]
10. Efficacy of real-time PCR-based detection of Helicobacter pylori infection and genotypic resistance-guided quadruple therapy as the first-line treatment for functional dyspepsia with Helicobacter pylori infection.
Liu Q; Qi D; Kang J; Jin Y; Liu W; Gao W; Hou P; Lu J
Eur J Gastroenterol Hepatol; 2015 Mar; 27(3):221-5. PubMed ID: 25629566
[TBL] [Abstract][Full Text] [Related]
11. Susceptibility-guided quadruple therapy is not superior to medication history-guided therapy for the rescue treatment of Helicobacter pylori infection: A randomized controlled trial.
Ji CR; Liu J; Li YY; Qiao C; Qu JY; Hu JN; Lin MJ; Ji R; Li LX; Zuo XL; Li YQ
J Dig Dis; 2020 Oct; 21(10):549-557. PubMed ID: 32833285
[TBL] [Abstract][Full Text] [Related]
12. Helicobacter pylori eradication rates using clarithromycin and levofloxacin-based regimens in patients with previous COVID-19 treatment: a randomized clinical trial.
Kamal A; Ghazy RM; Sherief D; Ismail A; Ellakany WI
BMC Infect Dis; 2023 Jan; 23(1):36. PubMed ID: 36670359
[TBL] [Abstract][Full Text] [Related]
13. Quantitative PCR of string-test collected gastric material: A feasible approach to detect Helicobacter pylori and its resistance against clarithromycin and levofloxacin for susceptibility-guided therapy.
Han X; Yu X; Gao X; Wang X; Tay CY; Wei X; Lai B; Marshall BJ; Zhang X; Chua EG
Helicobacter; 2023 Aug; 28(4):e12985. PubMed ID: 37066609
[TBL] [Abstract][Full Text] [Related]
14. Tailored eradication
Choi YI; Chung JW; Park DK; Kim KO; Kwon KA; Kim YJ; Seo JY
World J Gastroenterol; 2019 Dec; 25(46):6743-6751. PubMed ID: 31857776
[TBL] [Abstract][Full Text] [Related]
15. Success of susceptibility-guided eradication of
Wang YM; Chen MY; Chen J; Zhang XH; Feng Y; Han YX; Li YL
World J Gastroenterol; 2024 Jan; 30(2):184-195. PubMed ID: 38312120
[TBL] [Abstract][Full Text] [Related]
16. Clarithromycin-amoxycillin-containing triple therapy: a valid empirical first-line treatment for Helicobacter pylori eradication in Hong Kong?
Hung IF; Chan P; Leung S; Chan FS; Hsu A; But D; Seto WK; Wong SY; Chan CK; Gu Q; Tong TS; Cheung TK; Chu KM; Wong BC
Helicobacter; 2009 Dec; 14(6):505-11. PubMed ID: 19889067
[TBL] [Abstract][Full Text] [Related]
17. Comparison of Helicobacter pylori eradication rates between 7 and 14 days of tailored therapy according to clarithromycin resistance test: A randomized, multicenter, non-inferiority study.
Jung K; Jee SR; Lee MW; Koh M; Kim SJ; Lee J; Park MI
Helicobacter; 2024; 29(3):e13084. PubMed ID: 38717034
[TBL] [Abstract][Full Text] [Related]
18. Second-line rescue triple therapy with levofloxacin after failure of non-bismuth quadruple "sequential" or "concomitant" treatment to eradicate H. pylori infection.
Gisbert JP; Molina-Infante J; Marin AC; Vinagre G; Barrio J; McNicholl AG
Scand J Gastroenterol; 2013 Jun; 48(6):652-6. PubMed ID: 23556551
[TBL] [Abstract][Full Text] [Related]
19. Third-line rescue therapy with bismuth-containing quadruple regimen after failure of two treatments (with clarithromycin and levofloxacin) for H. pylori infection.
Gisbert JP; Perez-Aisa A; Rodrigo L; Molina-Infante J; Modolell I; Bermejo F; Castro-Fernández M; Antón R; Sacristán B; Cosme A; Barrio J; Harb Y; Gonzalez-Barcenas M; Fernandez-Bermejo M; Algaba A; Marín AC; McNicholl AG;
Dig Dis Sci; 2014 Feb; 59(2):383-9. PubMed ID: 24126798
[TBL] [Abstract][Full Text] [Related]
20. 14 day sequential therapy versus 10 day bismuth quadruple therapy containing high-dose esomeprazole in the first-line and second-line treatment of Helicobacter pylori: a multicentre, non-inferiority, randomized trial.
Liou JM; Chen CC; Fang YJ; Chen PY; Chang CY; Chou CK; Chen MJ; Tseng CH; Lee JY; Yang TH; Chiu MC; Yu JJ; Kuo CC; Luo JC; Hsu WF; Hu WH; Tsai MH; Lin JT; Shun CT; Twu G; Lee YC; Bair MJ; Wu MS;
J Antimicrob Chemother; 2018 Sep; 73(9):2510-2518. PubMed ID: 29846605
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
